MedTrace Logo

Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris

NCT02411942 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 753

Last updated 2017-05-04

No results posted yet for this study

Summary

The objectives of this study are to evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% and Differin® (adapalene gel 0.3%).

Conditions

  • Acne Vulgaris

Interventions

DRUG

Adapalene Gel 0.3%

Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days

DRUG

Differin®

Differin® applied to the entire face once daily for 84 consecutive days

DRUG

Placebo

Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days

Sponsors & Collaborators

  • Sun Pharmaceutical Industries, Inc.

    lead INDUSTRY

Principal Investigators

  • Catawba Research · http://catawbaresearch.com/contact/

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-02-28
Completion
2015-02-28

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02411942 on ClinicalTrials.gov